Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- SLE-BRAVE I (NCT03616912)
- Testing
- Baricitinib
- Where
- 184 sites in United States, Australia and 16 more
- Volunteers
- 830 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Systemic Lupus Erythematosus
Triptorelin for Ovary Protection in Childhood Onset Lupus
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to…
- Trial name
- NCT00124514
- Testing
- Triptorelin pamoate
- Where
- 10 sites in United States, Brazil
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Systemic Lupus Erythematosus, Arthritis
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
We hypothesize that mycophenolate mofetil(Cellcept)is safe and effective for lupus arthritis. In this study, patients with lupus will be randomly assigned to receive mycophenolate mofetil or placebo (inert pills) for three…
- Trial name
- NCT00594932
- Testing
- mycophenolate mofetil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Oklahoma Medical Research Foundation
Systemic Lupus Erythematosus
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.
- Trial name
- NCT01031836
- Testing
- MEDI-545, MEDI-545 600
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Cervical neoplasia is increased in women with SLE most likely due to cervical infection with human papilloma virus (HPV). 70% of cervical cancer is caused by HPV types 16 and 18.
- Trial name
- GARDASIL (NCT01741012)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Wayne State University
Systemic Lupus Erythematosus
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
This study will be conducted to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of anifrolumab given via the subcutaneous (SC) route of administration in adult Systemic Lupus Erythematosus (SLE) subjects…
- Trial name
- NCT02962960
- Testing
- Anifrolumab
- Where
- 14 sites in United States, Hungary and 2 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus (SLE)
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to…
- Trial name
- NCT03656562
- Testing
- VAY736, CFZ533
- Where
- 31 sites in Argentina, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.
- Trial name
- RECAST SLE OLE (NCT05430854)
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 7 more
- Volunteers
- 155 people
- Sponsor
- Amgen
HIV Infections, Systemic Lupus Erythematosus
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX® B/E) in HIV-uninfected adults…
- Trial name
- NCT03618056
- Testing
- AIDSVAX® B/E
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Reducing Disparities in Medication Adherence in SLE
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
- Trial name
- NCT03738826
- Testing
- Behavioral Intervention
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
- Trial name
- NCT02533570
- Testing
- Brentuximab vedotin
- Where
- 17 sites in United States
- Volunteers
- 20 people
- Sponsor
- Seagen Inc.
Systemic Lupus Erythematosus (SLE)
CCCR Lupus Patient Navigator Program
To address the health disparities in SLE outcomes for minorities, targeted intervention will be used to address the common barriers to care among patients; a comprehensive patient navigator approach will be utilized based on…
- Trial name
- NCT04461158
- Testing
- Patient Navigator Services
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Medical University of South Carolina
Lupus Nephritis
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
- Trial name
- NCT03943147
- Testing
- BMS-986165, Mycophenolate Mofetil
- Where
- 100 sites in United States, Australia and 14 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
- Trial name
- ISLAND-SLE (NCT04433585)
- Testing
- LY3471851
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 291 people
- Sponsor
- Nektar Therapeutics
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University